ArticleCell biomaterials2025
Synthetic peptides targeting a mast cell-specific G protein-coupled receptor MRGPRB2 display anti-infective potential.
Article in Cell biomaterials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Mast Cells in Host Defense Against Cutaneous Staphylococcus aureus Infection.Immunology and cell biology · 2026Review
- Printing to Fight Antimicrobial Resistance Through Nano/Microstructured Platforms.Chemical record (New York, N.Y.) · 2026Review
- Immunological mechanisms and novel therapeutic strategies for sepsis‑associated acute kidney injury (Review).International journal of molecular medicine · 2026Review
- A generative artificial intelligence approach for peptide antibiotic optimization.Nature machine intelligence · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Antibiotics are urgently needed against drug-resistant bacterial infections. We report synthetic peptides with dual antimicrobial and immunomodulatory action. These peptides activate the human Mas-related G protein-coupled receptor-X2 (MRGPRX2) and its mouse ortholog, Mas-related G protein-coupled receptor-B2 (MRGPRB2), while directly killing bacteria. Unlike traditional MRGPRX2 agonists, these peptides contain protease-resistant d-amino acids, enhancing their stability. In a mouse infection model, the peptides demonstrated antimicrobial efficacy, and activated human MRGPRX2 but not its G165E missense variant. They also stimulated tumor necrosis factor alpha (TNF-α), C-C motif chemokine ligand 3 (CCL3), and interleukin-8 (IL-8) release in human mast cells via MRGPRX2 and triggered degranulation in mouse mast cells via MRGPRB2. The peptides increased vascular permeability, promoted neutrophil and monocyte recruitment, and cleared
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.